Literature DB >> 11439365

Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.

E C Mommers1, A M Leonhart, F Falix, R Michalides, C J Meijer, J P Baak, P J Diest.   

Abstract

There is increasing evidence that there are different progression routes leading to invasive breast cancer, depending on histology and differentiation grade. The aim of this study was to determine alterations in the expression of proteins involved in proliferation and apoptosis in non-invasive and invasive ductal breast lesions. Immunohistochemistry was performed on 106 usual ductal hyperplasias (UDH), 61 DCIS lesions and 53 invasive ductal breast carcinomas. Increased proliferation (Ki67), overexpression of cyclin D1, HER-2/neu, p21 and p53, and decreased expression of bcl-2 and p27 could already be found in UDH. Significant differences between UDH and DCIS lesions were found for only one protein when UDH was compared with well-differentiated DCIS (p27), for three proteins when compared with intermediately differentiated DCIS (p21, cyclin D1, Ki-67), and for all proteins when compared with poorly-differentiated DCIS. Comparing DCIS with invasive lesions of same differentiation grade, proliferation was elevated in the invasive lesions. Altered expression of the other proteins was in general only slightly increased in the invasive lesion compared with DCIS. The number of proteins with altered expression per lesion was highest in poorly-differentiated lesions and was comparable between DCIS and invasive cancer of the same differentiation grade. In conclusion, the biggest changes in expression of these proliferation and apoptosis related proteins appear to occur during the transition from hyperplasia to DCIS; they probably play a minor role in the transition from DCIS to invasive breast lesion of same differentiation grade. Well-differentiated in situ and invasive breast lesions share many of the aberrations in expression of these proteins, as do poorly-differentiated in situ and invasive lesions. However, there are many differences between the well and poorly-differentiated lesions. This further supports the existence of different progression routes leading to breast cancer. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439365     DOI: 10.1002/path.910

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  12 in total

1.  Progression of Ductal Carcinoma in Situ from the Pathological Perspective.

Authors:  Pedro Oscar R Cunha; Mark Ornstein; J Louise Jones
Journal:  Breast Care (Basel)       Date:  2010-08-23       Impact factor: 2.860

2.  TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone.

Authors:  Florence Gizard; Romain Robillard; Barbara Gross; Olivier Barbier; Françoise Révillion; Jean-Philippe Peyrat; Gérard Torpier; Dean W Hum; Bart Staels
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

3.  Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia.

Authors:  Edgar S Díaz-Cruz; Priscilla A Furth
Journal:  Cancer Res       Date:  2010-05-15       Impact factor: 12.701

4.  TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1.

Authors:  Florence Gizard; Romain Robillard; Olivier Barbier; Brigitte Quatannens; Anne Faucompré; Françoise Révillion; Jean-Philippe Peyrat; Bart Staels; Dean W Hum
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

5.  Biological Markers Predictive of Invasive Recurrence in DCIS.

Authors:  Sharon Nofech-Mozes; Jacqueline Spayne; Eileen Rakovitch; Harriette J Kahn; Arun Seth; Jean-Phillippe Pignol; Lavina Lickley; Lawrence Paszat; Wedad Hanna
Journal:  Clin Med Oncol       Date:  2008-01-22

6.  Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study.

Authors:  Cathy B Moelans; Roel A de Wegers; Hanneke N Monsuurs; Anoek H J Maess; Paul J van Diest
Journal:  Cell Oncol (Dordr)       Date:  2011-05-06       Impact factor: 6.730

7.  Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ.

Authors:  P Wülfing; C Kersting; H Buerger; B Mattsson; R Mesters; C Gustmann; B Hinrichs; J Tio; W Böcker; L Kiesel
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

8.  Integrity of the LXXLL motif in Stat6 is required for the inhibition of breast cancer cell growth and enhancement of differentiation in the context of progesterone.

Authors:  Min Wei; Qi He; Zhongyin Yang; Zhiwei Wang; Qing Zhang; Bingya Liu; Qinlong Gu; Liping Su; Yingyan Yu; Zhenggang Zhu; Guofeng Zhang
Journal:  BMC Cancer       Date:  2014-01-08       Impact factor: 4.430

9.  Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related.

Authors:  Reinhard Bos; Paul J van Diest; Petra van der Groep; Avi Shvarts; Astrid E Greijer; Elsken van der Wall
Journal:  Breast Cancer Res       Date:  2004-06-09       Impact factor: 6.466

10.  DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.

Authors:  Rachel L Yang; Rosemarie Mick; Kathreen Lee; Holly L Graves; Katherine L Nathanson; Susan M Domchek; Rachel R Kelz; Paul J Zhang; Brian J Czerniecki
Journal:  J Transl Med       Date:  2015-10-24       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.